Dialysis water treated by reverse osmosis decreases the levels of C-reactive protein in uremic patients

Brazilian Journal of Medical and Biological Research

Volumn 38, Issue 5, 2005, Pages 789-794

  Thomé, Fernando S ^a,b,c   Senger, M ^b   Garcez, C ^a   Garcez, J ^a   Chemello, C ^a   Manfro, R C ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Hospital de Clínicas de Porto Alegre ^*  (Brazil)

Author keywords

C reactive protein; Dialysate water; Hemodialysis; Inflammation; Reverse osmosis; Uremia

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; ENDOTOXIN; FERRITIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; WATER;

ALBUMIN BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BACTERIUM COLONY; CLINICAL ARTICLE; CLONOGENIC ASSAY; DISEASE ASSOCIATION; FATALITY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; IONIZATION; MALE; METHODOLOGY; PROTEIN BLOOD LEVEL; REVERSE OSMOSIS; SURVIVAL; UREMIA; WATER ANALYSIS; WATER CONTAMINATION; WATER MANAGEMENT; WATER SUPPLY;

EID: 20944432378     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2005000500018     Document Type: Article

References (37)

1. Lindner A, Charra B, Sherrard DJ & Scribner BH (1974). Accelerated atherosclerosis in prolonged maintenance hemodialysis. New England Journal of Medicine, 290: 697-701.
2. Goodman WG, Goldin J, Kuizon BD et al. (2000). Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. New England Journal of Medicine, 342: 1478-1483.
3. United States Renal Data Systems, USRDS (2003). Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003. http//www.usrds.org/adr.htm. Accessed August 2003.
4. Yaqoob MM (2002). Emerging cardiovascular risk factors in end-stage renal disease. Journal of Nephrology, 15: 205-208.
5. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Grego F & Pauletto P (2003). New markers of accelerated atherosclerosis in end-stage renal disease. Journal of Nephrology, 16: 11-20.
6. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM & Stehouwer CD (2002). Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney International, 62: 1402-1407.
7. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA & Bergstrom J (2000). Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrology, Dialysis, Transplantation, 15: 953-960.
8. Stenvinkel P (2002). The malnutrition, inflammation, and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrology, Dialysis, Transplantation, 17 (Suppl 11): 28-31.
9. McIntyre C, Harper I, MacDougall C, Raine AE, Williams A & Baker LR (1997). Serum C-reactive protein as marker for infection and inflammation in regular dialysis patients. Clinical Nephrology, 48: 371-374.
10. Arici M & Walls J (2001). End-stage renal disease, atherosclerosis, and mortality: is C-reactive protein the missing link? Kidney International, 59: 407-414.
11. Wanner C, Zimmermann J, Schwedler S & Metzger T (2002). inflammation and cardiovascular risk in dialysis patients. Kidney International, 61: S99-S102.
12. Koenig W (2003). Update on C-reactive protein as risk marker in cardiovascular disease. Kidney International, 63: 58-61.
13. Kaysen GA (2002). Role of inflammation and its treatment in ESRD patients. Blood Purification, 20: 70-80.
14. Sociedade Brasileira de Nefrologia. Censo - Dezembro, 2002. http//www.sbn.org.br. Accessed May 2003.
15. Prior R (1990). The LAL test. In: Clinical Applications of the Limulus Amebocyte Lysate Test. CRC Press, Boston, MA, USA, 27-36.
16. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA & Jeejeebhoy KN (1987). What is subjective global assessment of nutritional status? Journal of Parenteral and Enteral Nutrition, 11: 8-13.
17. Martins C (2001). Protocolo de Procedimentos Nutricionais. In: Riella MC & Martins C (Editors), Nutrição e o Rim. Guanabara. Koogan S.A., Rio de Janeiro, RJ, Brazil, 311-344.
18. Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH & Luft FC (1999). A modified quantitative subjective global assessment of nutrition for dialysis patients. Nephrology, Dialysis, Transplantation, 14: 1732-1738.
19. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M & Koch K (1996). Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Peritoneal Dialysis International, 16: 158-162.
20. Cavaillon JM, Poignet JL, Fitting C & Delons S (1992). Serum interleukin-6 in long-term hemodialyzed patients. Nephron, 60: 307-313.
21. Pertosa G, Grandaliano G, Gesualdo L & Schena FP (2000). Clinical relevance of cytokine production in hemodialysis. Kidney International, 76: S104-S111.
22. Kunitoshi I, Tozawa M, Yoshi S & Fukiyama K (1999). Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrology, Dialysis, Transplantation, 14: 1956-1960.
23. Tetta C, David S, Mariano F, De Nitti C & Panichi V (2001). Alterations of the cytokine network in hemodialysis. Journal of Nephrology, 14: s22-s29.
24. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, Li PK & Sanderson J (2003). Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? Journal of the American Society of Nephrologry, 14: 1871-1879.
25. Yeun JY, Levine RA, Mantadilok V & Kaysen GA (2000). C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. American Journal of Kidney Diseases, 35: 469-476.
26. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B & Packer L (2002). Factors associated with oxidative stress in human populations. American Journal of Epidemiology, 156: 274-285.
27. Lonnemann G (2000). Chronic inflammation in hemodialysis: the role of contaminated dialysate. Blood Purification, 18: 214-223.
28. Canaud B, Bosc JY, Leray H, Morena M & Stec F (2000). Microbiologic purity of dialysate: rationale and technical aspects. Blood Purification, 18: 200-213.
29. Nubé MJ & Grooteman MP (2001). Impact of contaminated dialysate on long-term haemodialysis-related complications: is it really that important? Nephrology, Dialysis, Transplantation, 16: 1986-1991.
30. Tetta C, Panichi V, Wratten ML, Palla R & Lonneman G (1998). Plasma C-reactive protein is linked to backfiltration-associated interleukin-6 production. 44th Annual ASAIO Conference Abstract, New York, April 1998. American Society for Artificial Internal Organs Journal, 67A: 44.
31. Schiffl H, Lang SM, Stratakis D & Fischer R (2001). Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrology, Dialysis, Transplantation, 16: 1863-1869.
32. Jochimsen EM, Carmichael WW, An JS et al. (1998). Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil. New England Journal of Medicine, 338: 873-878.
33. Tarakcioglu M, Erbagci AB, Usalan C, Deveci R & Kocabas R (2002). Acute effect of hemodialysis on serum levels of the proinflammatory cytokines. Mediators of Inflammation, 12: 15-19.
34. Malaponte G, Bevelacqua V, Fatuzzo P, Rapisarda F, Emmanuele G, Travali S & Mazzarino MC (2002). IL-1β, TNF-α and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrology, Dialysis, Transplantation, 17: 1964-1970.
35. Kaysen GA (1999). Markers of chronic inflammation in CRF and factors that influence this chronic inflammatory state. Symposium of the American Society of Nephrology Annual Scientific Meeting, Miami, FL, USA, November 1999. http//www.HDCN.com. Accessed December 2002.
36. Bellomo G, Lippi G, Saronio P, Reboldi G, Verdura C, Timio F & Timio M (2003). Inflammation, infection and cardiovascular events in chronic hemodialysis patients: a prospective study. Journal of Nephrology, 16: 245-251.
37. Boenisch O, Ehmke KD, Heddergott A, Naoum C, Frei U & Schindler R (2002). C-reactive protein and cytokine plasma levels in hemodialysis patients. Journal of Nephrology, 15: 547-551.